📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: MultiVir

1.1 - Company Overview

MultiVir Logo

MultiVir

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.

Products and services

  • Ad-p53 Dendritic Cell Therapeutic Vaccine (Ad-p53-DCV): An adenoviral vector–transduced vaccine employing dendritic cells carrying p53 to activate the immune system against tumor cells
  • Ad-p53 Tumor Suppressor Immune Gene Therapy: An adenoviral vector–based therapy delivering normal p53 genes directly into tumors to restore tumor suppressor functions and stimulate anti-tumor immune responses
  • Ad-IL24 Tumor Suppressor Immune Gene Therapy: An adenoviral vector–mediated therapy delivering normal IL24 genes into tumors to reestablish tumor suppressor functions and enhance anti-tumor immune responses

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to MultiVir

Yourgene Health Logo

Yourgene Health

HQ: United Kingdom Website
  • Description: Provider of molecular diagnostics employing next generation DNA analysis technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Yourgene Health company profile →
Gen9 Logo

Gen9

HQ: United States Website
  • Description: Provider of next-generation gene synthesis technology enabling high-throughput, automated production of DNA constructs, designed to scale DNA content fabrication with lower cost and higher accuracy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Gen9 company profile →
Purigen Biosystems Logo

Purigen Biosystems

HQ: United States Website
  • Description: Provider of automated solutions for DNA and RNA purification using a proprietary approach with isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface; technology is agnostic to nucleic acid size or sequence.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Purigen Biosystems company profile →
Genable Technologies Logo

Genable Technologies

HQ: Ireland Website
  • Description: Provider of gene medicines to treat "dominant" genetic diseases, developed by a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company, based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genable Technologies company profile →
Cellmark Logo

Cellmark

HQ: United Kingdom Website
  • Description: Provider of DNA testing services, specializing in DNA analysis, paternity testing, and hair drug and alcohol testing, among others.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cellmark company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for MultiVir

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to MultiVir

2.2 - Growth funds investing in similar companies to MultiVir

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for MultiVir

4.2 - Public trading comparable groups for MultiVir

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to MultiVir

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About MultiVir

What does MultiVir do?

MultiVir is a provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.

Who are MultiVir's competitors?

MultiVir's competitors and similar companies include Yourgene Health, Gen9, Purigen Biosystems, Genable Technologies, and Cellmark.

Where is MultiVir headquartered?

MultiVir is headquartered in United States.

How many employees does MultiVir have?

MultiVir has 1,000 employees 🔒.

When was MultiVir founded?

MultiVir was founded in 2010 🔒.

What sector and industry vertical is MultiVir in?

MultiVir is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for MultiVir

Who are the top strategic acquirers in MultiVir's sector and industry

Top strategic M&A buyers and acquirers in MultiVir's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for MultiVir?

Top strategic M&A buyers groups and sectors for MultiVir include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in MultiVir's sector and industry vertical

Which are the top PE firms investing in MultiVir's sector and industry vertical?

Top PE firms investing in MultiVir's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in MultiVir's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in MultiVir's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in MultiVir's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to MultiVir include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in MultiVir's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for MultiVir?

The key public trading comparables and valuation benchmarks for MultiVir include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for MultiVir for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for MultiVir with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in MultiVir's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for MultiVir with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in MultiVir's' sector and industry vertical?

Access recent funding rounds and capital raises in MultiVir's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for MultiVir